Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc. has a strong outlook driven by the promising clinical development of its product candidate, pemvidutide, which targets metabolic dysfunction-associated steatohepatitis (MASH) through a dual receptor agonist mechanism. Recent industry movements, such as Novo’s acquisition of Akero Therapeutics, suggest growing confidence in the MASH therapeutic landscape and highlight the potential for pemvidutide to deliver significant metabolic and hepatic benefits without the complexities of combination dosing. Altimmune’s advancements, including leadership enhancements and robust clinical signals supporting pemvidutide’s tolerability and effectiveness, position the company well amidst a shift towards multi-mechanism strategies in treating metabolic and liver diseases.

Bears say

Altimmune Inc faces numerous risks that contribute to a negative outlook on its stock, primarily stemming from clinical development challenges associated with its product candidate, pemvidutide. The company is also exposed to competitive pressures, commercialization hurdles, and reimbursement uncertainties that could hinder market access and profitability. Additionally, potential disruptions due to external factors such as the ongoing geopolitical situation in Eastern Europe and the lingering effects of COVID-19 present further headwinds that could adversely affect the company's clinical trial timelines and overall financial stability.

Altimmune (ALT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 6 analysts, Altimmune (ALT) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.